Matinas BioPharma Holdings (MTNB) FCF Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) reported FCF Margin of 304.16% for Q2 2023, up 18370.0% year-over-year from N/an in Q2 2022, and up 72.09% quarter-over-quarter from 1089.87% in Q1 2023.
Matinas BioPharma Holdings (MTNB) FCF Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 8 years of FCF Margin data on file, last reported at 304.16% in Q2 2023.
- FCF Margin for Q2 2023 came in at 304.16%, up 18370.0% year-over-year; the trailing twelve-month figure through Dec 2023 was 1395.44% (down 76671.0% YoY), and the FY2023 annual result was 1413.87%, down 78501.0% from the prior year.
- FCF Margin improved to 304.16% in Q2 2023 per MTNB's latest filing, from 1089.87% in the prior quarter.
- Over five years, FCF Margin peaked at 1199121.32% in Q4 2021 and troughed at 13953.48% in Q1 2021.
- A 5-year average of 118109.97% and a median of 489.46% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2021 and 2022: FCF Margin soared 119226551 bps in 2021, then plunged 119952969 bps in 2022.
- A 5-year view of FCF Margin shows it stood at 2688.53% in 2019, then jumped by 355 bps to 6855.81% in 2020, then jumped by 17391 bps to 1199121.32% in 2021, then plunged by 100 bps to 408.37% in 2022, then advanced by 26 bps to 304.16% in 2023.
- Business Quant data shows MTNB's FCF Margin at 304.16% in Q2 2023, 1089.87% in Q1 2023, and 408.37% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -304.16% |
| Mar 31, 2023 | -1,089.87% |
| Dec 31, 2022 | -408.37% |
| Sep 30, 2022 | -491.06% |
| Jun 30, 2022 | -487.86% |
| Dec 31, 2021 | 1,199,121.32% |
| Mar 31, 2021 | -13,953.48% |
| Dec 31, 2020 | 6,855.81% |
| Sep 30, 2020 | -5,454.07% |
| Jun 30, 2019 | -2,688.53% |
| Jun 30, 2018 | -2,691.40% |
| Mar 31, 2018 | -9,712.55% |
| Dec 31, 2017 | -4,528.82% |
| Sep 30, 2017 | -6,277.44% |
| Jun 30, 2017 | -8,301.12% |
| Mar 31, 2017 | -20,253.41% |
| Sep 30, 2015 | -3,630.01% |
| Jun 30, 2015 | -2,922.68% |
| Mar 31, 2015 | -4,038.57% |